

Untitled

ALI GNMENT W TH SEQ I D NO: 2

ABN99362

ID ABN99362 standard; DNA; 1959 BP.

XX

AC ABN99362;

XX

DT 08- AUG 2002 (first entry)

XX

DE Human secreted protein (SCEP) coding sequence 3.

XX

KW Human; secreted protein; SECP; SECP expression; gene therapy;

KW protein therapy; immune system disorders; AIDS; thymic hypoplasia;

KW anaemia; asthma; Crohn's disease; neurological disorders; epilepsy;

KW Huntington's disease; dementia; Parkinson's disease; Down's syndrome;

KW developmental disorders; cell proliferative disorders; cancer; ds; gene.

XX

OS Homo sapiens.

XX

PN WO200226982-A2.

XX

PD 04- APR- 2002.

XX

PF 25- SEP- 2001; 2001WO-US030042.

XX

PR 29- SEP- 2000; 2000US-0236869P.

PR 11- OCT- 2000; 2000US-0239812P.

PR 12- OCT- 2000; 2000US-0240108P.

PR 17- OCT- 2000; 2000US-0241282P.

PR 20- OCT- 2000; 2000US-0242218P.

XX

PA (INCY-) INCYTE GENOMCS INC.

XX

PI Yue H, Tang YT, Nguyen DB, Yao MG, Xu Y, Trabouley CM;

PI Sanjwalan MS, Walia NK, Baughn MR, Sapperstein SK, Lal P;

PI Thornton M, Gandhi AR, Ramkumar J, Elliott VS, Arvizu C;

PI Thangavelu K, Getzen KJ, Ding L, Au-Young J, Tran B, Policky JL;

PI Lee S, Lu DAM, Burford N, Warren BA, Gururajan R, Duggan BM;

PI Honchel CD, Hafalia AJA;

XX

DR WPI ; 2002-394239/42.

DR P- PSDB; ABP43479.

XX

PT New human secreted proteins, useful for diagnosing, treating or

PT preventing immune system disorders (e.g. Crohn's disease), neurological

PT disorders (e.g. Parkinson's disease), or cell proliferative disorders

PT (e.g. cancers).

XX

PS Claim 5; Page 197; 238pp; English.

XX

CC The invention comprises the amino acid and coding sequences of human  
CC secreted proteins (SECP). The SECP DNA and amino acid sequences of the  
CC invention are useful for treating/preventing disorders associated with  
CC decreased or elevated expression of SECP. The SECP DNA and protein  
CC sequences are specifically useful for treating/preventing (i.e. gene  
CC therapy and protein therapy): immune system disorders (e.g. AIDS, thymic  
CC hypoplasia, anaemia, asthma or Crohn's disease); neurological disorders  
CC (e.g. epilepsy, Huntington's disease, dementia or Parkinson's disease);  
CC developmental disorders (e.g. Down's syndrome); and cell proliferative  
CC disorders (e.g. cancer). The nucleotides ABN99360 - ABN99428 encode the  
CC human secreted proteins (SECP) of the invention

## Untitled

XX  
 SQ Sequence 1959 BP; 346 A; 687 C; 605 G; 321 T; 0 U; 0 Other;  
 Query Match 98.0%; Score 1913.8; DB 6; Length 1959;  
 Best Local Similarity 99.9%; Pred. No. 0;  
 Matches 1915; Conservative 0; Missmatches 2; Indels 0; Gaps 0;

Qy 36 GCGCGGCTGGCGTGCCTCGCTCCCCGAAGCGGGGCTGGCGCGAGCGCGGGAGGGC 95  
 Db 1 GCGCGGCTGGCGTGCCTCGCTCCCCGAAGCGGGGCTGGCGCGAGCGCGGGAGGGC 60

Qy 96 TGGGAGCTGGCGGGTCCCCGGACAGCGGGGAGGGGAGCTGCCGGAGCGGGCAGCC 155  
 Db 61 TGGGAGCTGGCGGGTCCCCGGACAGCGGGGAGGGGAGCTGCCGGAGCGGGCAGCC 120

Qy 156 AGGCGGCTCAGGGCAGGGACAGCTGGCGCGGTTCTGGGTCTCCGGGCCAGATGTG 215  
 Db 121 AGGCGGCTCAGGGCAGGGACAGCTGGCGCGGTTCTGGGTCTCCGGGCCAGATGTG 180

Qy 216 AGGCGGCGGGCGGGGGGGGGGGAGAGCGCACGATGGGGGCGGCTCGCGTACGGCTGG 275  
 Db 181 AGGCGGCGGGCGGGGGGGGGGGAGAGCGCACGATGGGGGCGGCTCGCGTACGGCTGG 240

Qy 276 GCGCGCTCCACTACCTGGCACTTTCTGCAACTCGGGGGGCCACGCGGGGCCGGGCC 335  
 Db 241 GCGCGCTCCACTACCTGGCACTTTCTGCAACTCGGGGGGCCACGCGGGGCCGGGCC 300

Qy 336 ACGCGCCCTGGGACAACACCGTCTCGGCAACGCCCTGTTCACAGAGACACCCATGACA 395  
 Db 301 ACGCGCCCTGGGACAACACCGTCTCGGCAACGCCCTGTTCACAGAGACACCCATGACA 360

Qy 396 TGACACCACGGACGGGGAGGACGTGGAGATGGCTGCTCTTCCGGGGAGGGCTCCC 455  
 Db 361 TGACACCACGGACGGGGAGGACGTGGAGATGGCTGCTCTTCCGGGGAGGGCTCCC 420

Qy 456 CCTCCTACTCGCTGGAGATCCAGTGGGGATGTACGGAGCCACCGGACTGGACCGACA 515  
 Db 421 CCTCCTACTCGCTGGAGATCCAGTGGGGATGTACGGAGCCACCGGACTGGACCGACA 480

Qy 516 AGCAGGGTGGGCTCGAACCCAGCTAAACGATCTCAGCAGGAAGACGGAGGGAGGAGG 575  
 Db 481 AGCAGGGTGGGCTCGAACCCAGCTAAACGATCTCAGCAGGAAGACGGAGGGAGGAGG 540

Qy 576 CAACCAAAATAAGTGTGGTCAAGGTGGTGGGGAGCAACATCTCCACAAGCTGGCCTGT 635  
 Db 541 CAACCAAAATAAGTGTGGTCAAGGTGGTGGGGAGCAACATCTCCACAAGCTGGCCTGT 600

Qy 636 CCCGGGTGAAGCCCACGGACGAAGGCACCTACGAGTGGCGGTCTCGACTTCAGCGACG 695  
 Db 601 CCCGGGTGAAGCCCACGGACGAAGGCACCTACGAGTGGCGGTCTCGACTTCAGCGACG 660

Qy 696 GCAAGGGCCGGCACACAAGTCAAGGCCTACCTGGGGTGCAGGCCAGGGAGAACTCG 755  
 Db 661 GCAAGGGCCGGCACACAAGTCAAGGCCTACCTGGGGTGCAGGCCAGGGAGAACTCG 720

Qy 756 TCCTGCATCTGCCCGAAGGCCCTCCCCGCCGCCCCCCCCCAAGCCAGGCA 815  
 Db 721 TCCTGCATCTGCCCGAAGGCCCTCCCCGCCGCCCCCCCCCAAGCCAGGCA 780

Qy 816 AGGAGCTGAGGAAGCGCTGGTGGACCAAGGAGGGCTGCAGGCTCTAGACTGATGCCCTG 875  
 Db 781 AGGAGCTGAGGAAGCGCTGGTGGACCAAGGAGGGCTGCAGGCTCTAGACTGATGCCCTG 840

		Unt i t l ed	
Qy	876	CCCCCGCCCATCCGCCCCCACGCTGTACAGAGTGCATGAGGAGCCGCCCCGACCACCGGGG	935
Db	841	CCCCCGCCCATCCGCCCCCACGCTGTACAGAGTGCATGAGGAGCCGCCCCGACCACCGGGG	900
Qy	936	ACCGACTGCCTGCGTCCAGCCGCCCCATCCCCGAGGCCCCCTGTGGCCACCATGTCGG	995
Db	901	ACCGACTGCCTGCGTCCAGCCGTCGCCCCATCCCCGAGGCCCCCTGTGGCCACCATGTCGG	960
Qy	996	CCCTCTTCCACCAACCCCTTGCTCAGCATGTAAGCCCCACCCACCCCTGCCCTTCAGAC	1055
Db	961	CCCTCTTCCACCAACCCCTTGCTCAGCATGTAAGCCCCACCCACCCCTGCCCTTCAGAC	1020
Qy	1056	CCCTGCGGTGACCTGGCTGGAGAAGGTGGCCCTGGGACCAAGGGCAACCGCCCTGA	1115
Db	1021	CCCTGCGGTGACCTGGCTGGAGAAGGTGGCCCTGGGACCAAGGGCAACCGCCCTGA	1080
Qy	1116	ACACTGGGGCAGGGACCATGCTGGGCGCGGGGCAACCCCTTCTGTCAACCAGCTCTG	1175
Db	1081	ACACTGGGGCAGGGACCATGCTGGGCGCGGGGCAACCCCTTCTGTCAACCAGCTCTG	1140
Qy	1176	TGGAGTCCAGTGTGGCTTGTGGCTTGCTTGCTTGCTTGTCCCCATCCTGTCTGAGGCCCCCCCC	1235
Db	1141	TGGAGTCCAGTGTGGCTTGTGGCTTGCTTGCTTGCTTGTCCCCATCCTGTCTGAGGCCCCCCCC	1200
Qy	1236	CAGCCTCGCCTCCCTCCTACCATCCTCACTTGGACCTGGGGTGTGGACAGTGACC	1295
Db	1201	CAGCCTCGCCTCCCTCCTACCATCCTCACTTGGACCTGGGGTGTGGACAGTGACC	1260
Qy	1296	CCTCCCTGAATATGGACTTGAATCTTGTGACCAACTAGGGCTCTCCCCGGTGAAGA	1355
Db	1261	CCTCCCTGAATATGGACTTGAATCTTGTGACCAACTAGGGCTCTCCCCGGTGAAGA	1320
Qy	1356	CCCAGGGAACCCAGGAGGGCCCTCTGGGGCAGTGGCTCTGCAGGGTCACTCATGGAGC	1415
Db	1321	CCCAGGGAACCCAGGAGGGCCCTCTGGGGCAGTGGCTCTGCAGGGTCACTCATGGAGC	1380
Qy	1416	CTAGGGGAACAGGGAGATGCCCAACACCTCTGGGGAGTCTTCTGTTCAGCTCCCTG	1475
Db	1381	CTAGGGGAACAGGGAGATGCCCAACACCTCTGGGGAGTCTTCTGTTCAGCTCCCTG	1440
Qy	1476	TGGGACCCCTCAGGGATGCAGGGATCCAGGATTCTCTGCCCCGTACACGGGAGTCAG	1535
Db	1441	TGGGACCCCTCAGGGATGCAGGGATCCAGGATTCTCTGCCCCGTACACGGGAGTCAG	1500
Qy	1536	AAGGGAGGGCCTTCCCTCGGACCCATGGCCCCAGGCAGAGTTTGCAACCAGCAGGACC	1595
Db	1501	AAGGGAGGGCCTTCCCTCGGACCCATGGCCCCAGGCAGAGTTTGCAACCAGCAGGACC	1560
Qy	1596	CCTTGAGGGCCTCAAGGCTCTCCAGGAGTCCCCCTCTGCCGGCCCCCAATGCCCA	1655
Db	1561	CCTTGAGGGCCTCAAGGCTCTCCAGGAGTCCCCCTCTGCCGGCCCCCAATGCCCA	1620
Qy	1656	GCTCCCTCTTGGGTCTGTGCCAAGTCCGCCCCAGGGCTGGGGCTTGGGAGCCAAGG	1715
Db	1621	GCTCCCTCTTGGGTCTGTGCCAAGTCCGCCCCAGGGCTGGGGCTTGGGAGCCAAGG	1680
Qy	1716	GCCCCCTGGTACTCAGTCCCTCACGATTCCGATCACGGGACACCTGCCCCGGTAA	1775
Db	1681	GCCCCCTGGTACTCAGTCCCTCACGATTCCGATCACGGGACACCTGCCCCGGTAA	1740
Qy	1776	TTTGTAAATATTCATTGGACCCAAATTCTCTGGAAATTGGCTGGCACCTCTGGTGGC	1835
Db	1741	TTTGTAAATATTCATTGGACCCAAATTCTCTGGAAATTGGCTGGCACCTCTGGTGGC	1800

Untitled

Qy	1836	ACAGCTCAGT GATGACGT GGGGGAGGT GGGAGAGGCGAGGGCTT GCCTAGGGTGGT	1895
Db	1801	ACAGCTCAGT GATGACGT GGGGGAGGT GGGAGAGGCGAGGGCTT GCCTAGGGTGGT	1860
Qy	1896	TGCCCTGTATACATGATCCAGTCTGTGACTACCAGCCAACCTGAATAAGCGGTTT	1952
Db	1861	TGCCCTGTATACATGATCCAGTCTGTGACTACCAGCCAACCTGAATAAGCGGTTT	1917

\*\*\*\*\*

ALI GNMENT W TH SEQ I D NO: 66

ABP43479

ID ABP43479 standard; protein; 204 AA.

XX

AC ABP43479;

XX

DT 15-JUN-2007 (revised)

DT 08-AUG-2002 (first entry)

XX

DE Human secreted protein (SCEP) 3.

XX

KW Human; secreted protein; SECP; SECP expression; gene therapy;

KW protein therapy; immune system disorders; AIDS; thymic hypoplasia;

KW anaemia; asthma; Crohn's disease; neurological disorder; epilepsy;

KW Huntington's disease; dementia; Parkinson's disease; Down's syndrome;

KW developmental disorder; cell proliferative disorder; cancer; BOND\_PC;

KW chromosome 20 open reading frame 102;

KW chromosome 20 open reading frame 102 [Homo sapiens]; C20orf102;

KW DJ1118M15.2; hypotetical protein LOC128434;

KW hypotetical protein LOC128434 [Homo sapiens];

KW chromosome 20 open reading frame 102, isoform CRA\_a;

KW chromosome 20 open reading frame 102, isoform CRA\_a [Homo sapiens];

KW hypotetical protein; hypotetical protein [Homo sapiens];

KW unnamed protein; unnamed protein [Homo sapiens]; GO4872;

KW GO7166.

XX

OS Homo sapiens.

XX

PN WO200226982-A2.

XX

PD 04-APR-2002.

XX

PF 25-SEP-2001; 2001WO-US030042.

XX

PR 29-SEP-2000; 2000US-0236869P.

PR 11-OCT-2000; 2000US-0239812P.

PR 12-OCT-2000; 2000US-0240108P.

PR 17-OCT-2000; 2000US-0241282P.

PR 20-OCT-2000; 2000US-0242218P.

XX

PA (INCY-) INCYTE GENOMICS INC.

XX

PI Yue H, Tang YT, Nguyen DB, Yao MG, Xu Y, Tribble CM;

PI Sanjwalan MS, Walia NK, Baughn MR, Sapperstein SK, Lal P;

PI Thornton M, Gandhi AR, Ramkumar J, Elliott VS, Arvizu C;

PI Thangavelu K, Getzen KJ, Ding L, Au-Young J, Tran B, Policky JL;

PI Lee S, Lu DAM, Burford N, Warren BA, Gururajan R, Duggan BM;

PI Honchell CD, Hafalia AJA;

XX

DR WPI; 2002-394239/42.

DR N-PSDB; ABN99362.

Untitled

DR PC: NCBI ; gi 18079321.  
DR PC: SWI SSPROT; Q96N03.

PT New human secreted proteins, useful for diagnosing, treating or preventing immune system disorders (e.g. Crohn's disease), neurological disorders (e.g. Parkinson's disease), or cell proliferative disorders (e.g. cancers).

XX

PS Claim 1; Page 151-152; 238pp; English.

XX  
CC The invention comprises the amino acid and coding sequences of human  
CC secreted proteins (SECP). The SECP DNA and amino acid sequences of the  
CC invention are useful for treating/preventing disorders associated with  
CC decreased or elevated expression of SECP. The SECP DNA and protein  
CC sequences are specifically useful for treating/preventing (i.e. gene  
CC therapy and protein therapy): immune system disorders (e.g. AIDS, thymic  
CC hypoplasia, anaemia, asthma or Crohn's disease); neurological disorders  
CC (e.g. epilepsy, Huntington's disease, dementia or Parkinson's disease);  
CC developmental disorders (e.g. Down's syndrome); and cell proliferative  
CC disorders (e.g. cancer). The proteins ABP43477 - ABP43543 represent the  
CC human secreted proteins (SECP) of the invention.

CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed  
CC information from BOND.

xx

SQ Sequence 204 AA;

Query Match 100.0% Score 1092; DB 5; Length 204;  
Best Local Similarity 100.0% Pred. No. 1.7e-92;  
Matches 204; Conservative 0; Missmatches 0; Indels 0; Gaps 0;

Qy 1 MGAPLAVALGALHYLALFLQLGGATRPAAGHAPWDNIVSGHALFTETPHDMTARTGEDVEM 60

MEGLAFLAVALGALYTLALPFLQEGGATRPAAGHAPWDNHVSQHAFTEPFRHDMIAARTGQEDVEM 60

Qy 61 ACSERGSGSPSYSL EI QWWVRSRHDW DKQAWASNLKASQEDAGKAEATK SWVKVG 120  
Ph 61 ACSERGSGSPSYSL EI QWWVRSRHDW DKQAWASNLKASQEDAGKAEATK SWVKVG 120

Qy 121 SNI SHKLRLSRVKPTDEGTYECRVI DFSDGKARHHVKAYL RVQPGENSL HLPEAPPAA 180

Db 121 SNI SHKLRLSRVKPTDEGYECRVI DFSDGKARHHVKAYL RVQPGENSLVHLPEAPPAA 180

101 HAWAIIAN GREEN KNOWLEDGE VOL 204

181 | ANNUAL REPORT 2014 | SUSTAINABILITY REPORT 2014